Jorgensen Nathan D. 4

What Happened

• Nathan D. Jorgensen, Chief Financial Officer of Voyager Therapeutics (VYGR), disposed of 4,668 shares on February 24, 2026. The weighted average sale price was $3.77 per share, for total proceeds of approximately $17,598.
• This was a sale (not a purchase) and was executed as a sell‑to‑cover to satisfy tax withholding related to restricted stock units that vested on February 21, 2026. The filing notes the sales were not discretionary.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (timely).
• Price: weighted average $3.77; individual sale prices ranged from $3.61 to $3.86.
• Shares sold: 4,668; proceeds ≈ $17,598.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: (1) Sales made pursuant to a durable automatic sale instruction (sell‑to‑cover) adopted May 9, 2025, to satisfy tax withholding for RSU vesting; not a discretionary trade. (2) Weighted average price reported; reporting person will provide per‑price breakdown on request.
• Remarks: Exhibit 24.1 (Limited Power of Attorney) attached to the filing.

Context

• Sell‑to‑cover transactions are routine tax‑related sales that occur when RSUs vest and the company (or reporting person) sells a portion of the shares to cover taxes; they generally do not indicate an insider’s view on the stock.
• The filing shows a routine disposal related to compensation tax withholding rather than an open‑market, discretionary sale intended to express a view on company prospects.